Compounds > fingolimod hydrochloride
Page last updated: 2024-09-02

fingolimod hydrochloride and Hypertension

fingolimod hydrochloride has been researched along with Hypertension in 13 studies

Research

Studies (13)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (7.69)29.6817
2010's9 (69.23)24.3611
2020's3 (23.08)2.80

Authors

AuthorsStudies
Gu, ZC; Lv, Y; Ma, CL; Zhao, Z; Zhong, MK1
Marulanda, E; Tornes, L1
Cui, H; Gu, C; Kim, LJ; Lee, R; Mitrut, R; Pham, L; Polotsky, VY; Sham, JSK; Shin, MK; Tang, WY; Yeung, BHY1
Cantalupo, A; Dautaj, E; Di Lorenzo, A; Gargiulo, A; Hla, T; Liu, C; Zhang, Y1
Ioka, T; Iwazu, K; Iwazu, Y; Kusano, E; Muto, S; Nagata, D; Watanabe, Y1
Jiménez-Altayó, F; Jurado, A; Meissner, A; Miro, F; Planas, AM; Vila, E1
Binder, E; Budde, K; Khadzhynov, D; Krämer, S; Loof, T; Martini, S; Neumayer, HH; Peters, H; Wang-Rosenke, Y1
Alewijnse, AE; Peters, SL; Spijkers, LJ1
Buja, LM; Haden-Pinneri, K; Lindsey, JW; Memon, NB1
Cocco, G1
Bermel, RA; Cohen, JA; Hara-Cleaver, C; Ontaneda, D; Rudick, RA1
Chen, RR; Dinallo, RM; Fryer, RM; Harrington, KE; Harrison, PC; Horan, JC; Modis, LK; Muthukumarana, A; Nodop Mazurek, S; Patnaude, L; Reinhart, GA1
Merkely, B; Széplaki, G1

Reviews

2 review(s) available for fingolimod hydrochloride and Hypertension

ArticleYear
Risk for Cardiovascular Adverse Events Associated With Sphingosine-1-Phosphate Receptor Modulators in Patients With Multiple Sclerosis: Insights From a Pooled Analysis of 15 Randomised Controlled Trials.
    Frontiers in immunology, 2021, Volume: 12

    Topics: Azetidines; Benzyl Compounds; Bradycardia; Drug-Related Side Effects and Adverse Reactions; Fingolimod Hydrochloride; Humans; Hypertension; Indans; Multiple Sclerosis; Oxadiazoles; Randomized Controlled Trials as Topic; Risk; Sphingosine 1 Phosphate Receptor Modulators; Sphingosine-1-Phosphate Receptors

2021
[Clinical significance of the cardiovascular effects of fingolimod treatment in multiple sclerosis].
    Ideggyogyaszati szemle, 2012, Nov-30, Volume: 65, Issue:11-12

    Topics: Atrioventricular Block; Bradycardia; Cardiovascular System; Clinical Trials as Topic; Drug Administration Schedule; Fingolimod Hydrochloride; Heart Conduction System; Humans; Hypertension; Immunosuppressive Agents; Interferon beta-1a; Interferon-beta; Multiple Sclerosis; Propylene Glycols; Receptors, Lysosphingolipid; Secondary Prevention; Sphingosine; Treatment Outcome

2012

Other Studies

11 other study(ies) available for fingolimod hydrochloride and Hypertension

ArticleYear
Obstetric and Gynecologic Disorders and the Nervous System.
    Continuum (Minneapolis, Minn.), 2023, 06-01, Volume: 29, Issue:3

    Topics: Breast Feeding; Female; Fingolimod Hydrochloride; Humans; Hypertension; Multiple Sclerosis; Pregnancy

2023
Pharmacological and Genetic Blockade of
    Hypertension (Dallas, Tex. : 1979), 2021, Volume: 78, Issue:1

    Topics: Animals; Blood Pressure; Carotid Body; Fingolimod Hydrochloride; Hydrogels; Hypertension; Immunosuppressive Agents; Leptin; Male; Mice, Inbred C57BL; Mice, Knockout; Obesity; RNA Interference; TRPM Cation Channels

2021
S1PR1 (Sphingosine-1-Phosphate Receptor 1) Signaling Regulates Blood Flow and Pressure.
    Hypertension (Dallas, Tex. : 1979), 2017, Volume: 70, Issue:2

    Topics: Animals; Blood Pressure; Disease Models, Animal; Endothelial Cells; Fingolimod Hydrochloride; Hypertension; Immunosuppressive Agents; Mice; Nitric Oxide; Nitric Oxide Synthase Type III; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine-1-Phosphate Receptors

2017
Multiple Sclerosis Drug Fingolimod Induces Thrombotic Microangiopathy in Deoxycorticosterone Acetate/Salt Hypertension.
    Hypertension (Dallas, Tex. : 1979), 2018, Volume: 72, Issue:3

    Topics: Animals; Arterioles; Blood Pressure; Desoxycorticosterone Acetate; Endothelium, Vascular; Fingolimod Hydrochloride; Humans; Hypertension; Kidney; Male; Multiple Sclerosis, Relapsing-Remitting; Nephrectomy; Nitric Oxide Synthase Type III; Rats, Sprague-Dawley; Sodium Chloride; Thrombotic Microangiopathies

2018
Sphingosine-1-phosphate signalling-a key player in the pathogenesis of Angiotensin II-induced hypertension.
    Cardiovascular research, 2017, Volume: 113, Issue:2

    Topics: Adoptive Transfer; Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Bone Marrow Transplantation; Cell Movement; Disease Models, Animal; Fingolimod Hydrochloride; Genetic Predisposition to Disease; Hypertension; Inflammation Mediators; Lymph Nodes; Lysophospholipids; Mesenteric Arteries; Mice, Inbred C57BL; Mice, Knockout; Phenotype; Phosphotransferases (Alcohol Group Acceptor); Receptors, Lysosphingolipid; Signal Transduction; Sphingosine; T-Lymphocytes; Time Factors; Vascular Remodeling

2017
The lymphocyte migration inhibitor FTY720 attenuates experimental hypertensive nephropathy.
    American journal of physiology. Renal physiology, 2009, Volume: 297, Issue:1

    Topics: Animals; Blood Pressure; Cell Movement; Cell Proliferation; Disease Models, Animal; Extracellular Matrix; Fibrosis; Fingolimod Hydrochloride; Hypertension; Immunosuppressive Agents; Kidney; Kidney Diseases; Lymphocytes; Macrophages; Male; Nephrectomy; Propylene Glycols; Proteinuria; Rats; Rats, Wistar; Sphingosine; Transforming Growth Factor beta

2009
FTY720 (fingolimod) increases vascular tone and blood pressure in spontaneously hypertensive rats via inhibition of sphingosine kinase.
    British journal of pharmacology, 2012, Volume: 166, Issue:4

    Topics: Animals; Blood Pressure; Carotid Arteries; Cyclooxygenase Inhibitors; Endothelium, Vascular; Enzyme Inhibitors; Fingolimod Hydrochloride; Hypertension; Immunosuppressive Agents; Isoenzymes; Male; Muscle, Smooth, Vascular; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Sphingosine; Thromboxane A2; Vascular Resistance; Vasoconstrictor Agents

2012
Sudden unexpected death on fingolimod.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2012, Volume: 18, Issue:10

    Topics: Arrhythmias, Cardiac; Death, Sudden, Cardiac; Female; Fingolimod Hydrochloride; Humans; Hypertension; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine

2012
A patient with Leiden V mutation, multiple sclerosis, psoriasis, and sicca syndrome: could celecoxib and fingolimod adversely affect the heart?
    Cardiovascular toxicology, 2012, Volume: 12, Issue:3

    Topics: Arthritis, Psoriatic; Atrial Fibrillation; Autoimmune Diseases; Celecoxib; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Factor V; Fingolimod Hydrochloride; Heart; Heart Diseases; Heart Failure; Humans; Hypertension; Immunosuppressive Agents; Male; Middle Aged; Mitral Valve Insufficiency; Multiple Sclerosis; Mutation; Myocardium; Propylene Glycols; Pyrazoles; Sjogren's Syndrome; Sphingosine; Sulfonamides

2012
Early tolerability and safety of fingolimod in clinical practice.
    Journal of the neurological sciences, 2012, Dec-15, Volume: 323, Issue:1-2

    Topics: Adult; Bradycardia; Chest Pain; Drug Substitution; Female; Fingolimod Hydrochloride; Headache; Humans; Hypertension; Lymphopenia; Macular Edema; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Nausea; Patient Acceptance of Health Care; Product Surveillance, Postmarketing; Propylene Glycols; Retrospective Studies; Sphingosine

2012
The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P₁) and hypertension (S1P₃) in rat.
    PloS one, 2012, Volume: 7, Issue:12

    Topics: Animals; Azetidines; Benzyl Compounds; Bradycardia; Cells, Cultured; Drug Evaluation, Preclinical; Fingolimod Hydrochloride; Humans; Hypertension; Immunosuppressive Agents; Male; Propylene Glycols; Rats; Rats, Sprague-Dawley; Receptors, Lysosphingolipid; Sphingosine; Substrate Specificity

2012